Blueprint Medicines Corporation Claimed Company
Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to?rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering approved medicines directly to patients in the United States and Europe, and we are globally advancing multiple programs for systemic mastocytosis, lung cancer and other genomically defined cancers, and cancer immunotherapy. read more
Lynn Seely M.D. ā Director at Blueprint Medicines Corporation
Executive Bio
Dr. Lynn Seely, MD serves as Principal Executive Officer at Myovant Sciences Ltd. and serves as its an Executive Director. Dr. Seely has been the President and Chief Executive Officer of Myovant Sciences, Inc. since May 2016. She served as the Chief Medical Officer of Medivation, Inc. (formerly Orion Acquisition Corp. II) from May 9, 2005 to October 15, 2015 and served as its Consultant from October 15, 2015 to April 15, 2016. Dr. Seely was responsible for the strategy and execution of Orion Acquisition Corp. II's clinical development programs and for assisting in the evaluation of new opportunities to expand. She has more than 20 years of cross-functional expertise within the healthcare industry, including experience in clinical and product development, business development and regulatory affairs. Dr. Seely served as a Vice President of Clinical Development at Anesiva, Inc. (formerly, Corgentech Inc.), from September 2002 to 2005. At Corgentech, Dr. Seely was responsible for all aspects of a large Phase III cardiovascular trial of an E2F decoy and for the strategy and development of a second clinical program for another new chemical entity. Dr. Seely served as a Vice President of Clinical Development at Cytyc Health Corporation and ProDuct Health, Inc. from 2000 to 2001 and was responsible for clinical trial strategy and execution and physician training during commercialization of a novel breast cancer device. Dr. Seely served as a Vice President of Clinical Development for Cytyc Health Corporation's subsidiary of Cytyc Corporation from 2001 to 2002, where she assisted with transitional matters related to Cytyc Corporations acquisition of ProDuct Health, Inc. From 1996 to 2000, Dr. Seely served as an Associate Director of Clinical Development at Chiron Corporation, a biotechnology company where she served for more than four years in clinical development at Chiron Corporation and worked on a broad range of development programs in multiple different therapeutic areas. From July 1992 to November 1996, Dr. Seely served as an Assistant Professor of Medicine at the University of California, San Diego, where she ran a National Institute of Health-funded growth factor signal transduction laboratory and was co-director of the fellowship training program in Endocrinology and Metabolism. She has been a Director of Blueprint Medicines Corporation since April 15, 2016. After serving as Chief Resident in Medicine at Yale, she completed a post-doctoral fellowship in Endocrinology and Metabolism at the University of California, San Diego. Dr. Seely holds a B.A. in Journalism from the University of Oklahoma. Dr. Seely holds a Medical Degree from the University of Oklahoma College of Medicine and completed her residency in Internal Medicine at the Yale-New Haven Hospital in New Haven, Conn.
Key Executives
Name
Title
Salary
Total Comp Total Compensation includes both short-term and long-term benefits, option grants, salary, bonuses, company perks, etc. that can be used to determine financial benefits. An executive may or may not realize all of the Total Co mpensation during their tenure at the Company. Values of the benefits may change over time.
Executive Team Culture Ratings from Blueprint Medicines Corporation Employees
TOP
5%
Blueprint Medicines Corporation's Executive Team scores in the Top 5%
of similar sized companies on Comparably
of similar sized companies on Comparably
Blueprint Medicines Corporation's Executive Team at a Glance
Based on 160 ratings, Blueprint Medicines Corporation's employees are very satisfied with their Executive Team and give them an āA+ā or 90/100. On average, Women provided higher ratings for their Executive Team compared to Men. Also, the COO department thinks more highly of the Executive Team relative to the Sales department.
Blueprint Medicines Corporation's Executive Team ranks in the Top 5% of other companies in Boston and Top 5% of other companies on Comparably that also have 501-1,000 Employees.
×